Background Development of a nonendoscopic test for Barrett's esophagus would revolutionize population screening and surveillance for patients with Barrett's esophagus. Swallowed cell collection devices have recently been developed to obtain cytology brushings from the esophagus: automated detection of neoplasia in such samples would enable large-scale screening and surveillance. Methods Fourier transform infrared (FTIR) spectroscopy was used to develop an automated tool for detection of Barrett's esophagus and Barrett's neoplasia in esophageal cell samples. Cytology brushings were collected at endoscopy, cytospun onto slides and FTIR images were measured. An automated cell recognition program was developed to identify individual cells on the slide. Results Cytology review and contemporaneous histology was used to inform a training dataset containing 141 cells from 17 patients. A classification model was constructed by principal component analysis fed linear discriminant analysis, then tested by leave-one-sample-out cross validation. With application of this training model to whole slide samples, a threshold voting system was used to classify samples according to their constituent cells. Across the entire dataset of 115 FTIR maps from 66 patients, whole samples were classified with sensitivity and specificity respectively as follows: normal squamous cells 79.0% and 81.1%, nondysplastic Barrett's esophagus cells 31.3% and 100%, and neoplastic Barrett's esophagus cells 83.3% and 62.7%. Conclusions Analysis of esophageal cell samples can be performed with FTIR spectroscopy with reasonable sensitivity for Barrett's neoplasia, but with poor specificity with the current technique.
Background
The current British Society of Gastroenterology guidelines list several developments that would ''revolutionize the care of individuals with Barrett's esophagus and should be priorities for policy makers and funders,'' of which the number one item listed is ''a non-endoscopic test(s) for diagnosis and surveillance'' [1] . Development of an accurate, minimally invasive, relatively low-cost test could radically alter current models of endoscopic surveillance, and overcome the greatest obstacles to screening patients for Barrett's esophagus; namely, the cost, acceptability, and risks of endoscopy. Swallowed cell collection devices offer a potential nonendoscopic means of sampling from the esophagus. Balloon collection devices have been used in eastern Asia for several decades as a screening tool for squamous cell carcinoma of the esophagus [2] [3] [4] . A balloon device has been trialed for Barrett's esophagus associated neoplasia, but challenges included inadequate cell collection and reduced sensitivity for dysplasia [5] . Results from the same study suggested that brush cytology has the potential to collect a representative sample, but the difficulty of interpretation of low-grade dysplasia may limit the sensitivity when conventional cytological assessment is used.
If a swallowed cell collection device were to be used as a screening tool for Barrett's esophagus, this would pose a number of challenges for conventional cytological assessment. Firstly, esophageal cytology is performed relatively infrequently, and expertise in this field is correspondingly limited. Secondly, assessment of cells may be challenging, and shows variable correlation with contemporaneous histological findings [6] [7] [8] . Thirdly, a swallowed device that enters the stomach may have glandular cells from the stomach, and these must be differentiated from esophageal glandular metaplasia. Fourthly, if expert cytological assessment were required for every sample collected as part of population screening, this would require significant resources.
The recently developed Cytosponge device aims to overcome a number of these challenges through immunostaining with trefoil factor 3, with promising results for detection of Barrett's esophagus [9, 10] .
An alternative approach to conventional cytological cell classification uses Fourier transform infrared (FTIR) spectroscopy. In FTIR spectroscopy, infrared radiation is passed through a sample. Some of the infrared radiation is absorbed by the sample and some of it passes through (i.e., it is transmitted). The resulting spectrum represents the molecular absorption and transmission, creating a molecular fingerprint of the sample based on its biomolecular composition. This makes infrared spectroscopy useful for several types of analysis.
Subtle variations in sample biochemistry can be detected, highlighting different pathological states, and FTIR spectra can be used to build classification models to assign pathology labels to a range of biomedical samples [11] .
To date there have been a small number of studies showing the ability of FTIR spectroscopy to classify Barrett's esophagus using esophageal tissue [12] [13] [14] , and only one small study showing feasibility of detection of Barrett's esophagus using esophageal cells [15] . The present study was designed as a larger study to evaluate FTIR spectroscopy as a means for detecting Barrett's neoplasia in esophageal cells from brush cytology samples.
Methods

Sample collection
Although the long term goal is nonendoscopic cell collection, samples in this study were taken under direct vision during endoscopy to allow contemporaneous biopsy and rigorous inclusion criteria to inform a training dataset.
Ethics approval was obtained for this study, and all patients participating in the study provided informed consent. Samples were collected from patients undergoing scheduled endoscopy for Barrett's esophagus surveillance. To enrich the sample population for patients with esophageal adenocarcinoma, some samples were also collected from patients undergoing surgery for esophageal cancer. Normal esophageal squamous cells, used as controls, were collected from patients undergoing routine endoscopy in whom no endoscopic or histological abnormality was identified.
Cytology samples were collected during endoscopy with an endoscopic cytology brush passed down the instrument channel of an endoscope, under direct vision during endoscopy. The cytology brush containing the cells was then stored in formalin at room temperature until slide preparation.
To be certain that the cells included in the training dataset were representative of the specified disease, a biopsy sample was taken from the area after cell collection, and only those cells whose cytological appearance was consistent (on review by two cytopathologists) with the contemporaneous endoscopy and biopsy results were included. In cases where the cytology and histology results did not agree, the cells were not included in the training model.
For later analysis of whole samples included in the test dataset, the classification of the whole sample was based on the endoscopy and biopsy result as the gold standard. To further remove the possibility of misclassification, patients were only included in the test dataset if they had no history of more advanced disease (i.e., to be included as a normal control they must have had no history of Barrett's esophagus, and to be included as a Barrett's esophagus case they must have had no history of esophageal dysplasia/ adenocarcinoma).
Sample measurement
Cell samples were transferred to calcium fluoride slides for measurement; a detailed protocol of this procedure is included in the electronic supplementary material.
Samples were measured in the Biophotonics Unit at Gloucestershire Royal Hospital with a PerkinElmer Spectrum One FTIR spectrometer with a PerkinElmer Spotlight 400 imaging system. Infrared absorption maps were obtained in transmission mode, with raster scanning at 6.25 lm per pixel, with 4-cm -1 spectral resolution across a wavenumber range of 750-4000 cm -1 . An initial background reading was taken with 120 scans per pixel from an acellular region of the slide. Maps of infrared absorption were collected across a 4 mm 9 2 mm region of each slide, measuring two scans per pixel.
Data processing: automated identification of cells
Our intention was to develop a system that used mapping to measure large areas and then automatically identify cells within the measured region. An automated measurement system could then be used to analyze cells on a slide without our having to visually identify and measure each cell individually.
Initial data processing steps were applied to enhance signal-to-noise ratios in the measured cell spectra, and prepare the spectra for further analysis. A postprocessing algorithm was developed to detect cellular regions and extract the spectra from these regions, assigning each to a particular cell. The spectra measured from each individual cell could then be analyzed and a classification label could be assigned to that particular cell. The preprocessing steps and postprocessing algorithm are described further in the electronic supplementary material. Similar techniques have been described previously by a number of authors [16] [17] [18] .
Development of a training dataset
The training dataset was composed of cells from a preliminary group of patients. After identification by the binary mask algorithm, cells whose classification on appearance by two cytopathologists was in agreement with contemporaneous endoscopy and biopsy results from the same region were included. The dysplasia/adenocarcinoma group included any degree of dysplasia (low or high grade), but samples classified as ''indefinite for dysplasia'' were excluded.
Multivariate analysis was then performed to identify spectral differences between cells from the different pathology groups to make possible classification based on cell spectra. Principal component analysis was used to identify variance between the spectra and reduce the complexity of the dataset. Linear discriminant analysis was then used to incorporate information about which pathology groups the spectra came from, and build diagnostic classification models. Diagnostic classification models were then tested by leave-one-sample-out cross validation: each sample was sequentially tested in training models that contain data from every sample except the one being tested.
Classification models developed with the training dataset could then be applied to the full dataset to classify whole samples from individual patients. Cells that were included in the training dataset were excluded from the test set to prevent overestimation of performance.
Since not every cell on a slide would necessarily have the same classification, a ''threshold voting'' system was used to assign a classification to a given sample. For example, a 30% threshold per cell would mean that if 30% or more spectra from that cell were classified as dysplastic, the entire cell is classified as dysplastic. Similarly, if 30% or more cells on a slide are found to be dysplastic, the sample is classified as dysplastic. This is a higher threshold than that used by cytologists, whereby the presence of any dysplasia is sufficient for classification as dysplastic, but aimed to ensure higher specificity when very large numbers of cells were being tested for each patient.
Results
Training dataset
The training dataset was developed with 141 cells from 17 patients (8 normal squamous cells, 4 Barrett's esophagus, 5 dysplasia/adenocarcinoma), with a total of 1480 spectra. The data included in the training dataset are shown in Table 1 .
A classification model was constructed with use of principal component analysis fed linear discriminant analysis. The linear discriminant functions are shown in Fig. 1 . Linear discriminant analysis achieves good grouping and separation of each of the pathology groups, but there remains a cluster of Barrett's esophagus datapoints close to the other two groups. Every one of these outlying datapoints was from a single sample.
The performance of the training dataset classification model was then tested by leave-one-sample-out cross validation: the results are shown in Table 2 .
The sensitivity of the model for individual spectra is reasonably good for normal squamous cells at 83.6%, but only moderate for the Barrett's esophagus and dysplasia/ adenocarcinoma cells. The standard deviation was largest for the normal squamous cells, as would be expected since the cells chosen were different for each iteration. The size of the variation in the sensitivity for the dysplasia/adenocarcinoma group reflects the overlap with the normal squamous cells, and hence this varies depending on which cells are included. There was very little variation in the Barrett's esophagus result, with a small standard deviation.
Spectral differences between pathology groups
The mean spectra from each of the three pathology groups are shown in Fig. 2 . The spectra are presented as second derivatives to clarify the position of spectral peaks and highlight differences between the groups.
Assigning biochemical labels to spectral peaks is tentative, as there are frequently multiple possible bond vibrations that can give a spectral peak at a given wavenumber. However, on the basis of previous studies in esophageal tissue [12] [13] [14] and previous work by the group in esophageal tissue [19] , a number of important differences are seen between the pathology groups in this study. The Barrett's esophagus and dysplasia/adenocarcinoma groups have an additional spectral peak at 969 cm -1 that probably represents DNA, and may reflect a higher DNA content in these cell types. At one of the key glycoprotein regions around 1080 cm -1 , the Barrett's esophagus group shows a doublet, with peaks at 1067 and 1084 cm -1 , whereas the normal squamous cell and dysplasia/adenocarcinoma groups have a single peak at 1077 cm -1 . This may be due to differences or an increase in mucin content within the Barrett's esophagus cells. There are three peaks corresponding to glycogen in the normal squamous cells, at 995, 1024, and 1153 cm -1 : these peaks are either smaller or show different configurations in the Barrett's esophagus and dysplasia/adenocarcinoma groups, which may reflect a lower glycogen content in these cell, as might be expected with their pathological state.
Test dataset
The classification model developed from the training dataset was then applied to the full dataset. The steps involved are illustrated in Fig. 3 : first the binary mask algorithm was used to identify individual cells on each slide, then the classification model was applied to assign a pathology label to each cell on the slide on the basis of its FTIR spectra, then an overall pathology classification was given to each slide. This predicted pathological state was compared against the biopsy result from the same region, and sensitivity and specificity were calculated with this gold standard.
The number of samples and spectra included in the test dataset (after the same preprocessing steps as those applied to the training dataset) are shown in Table 3 .
The results from application of the training model to this test dataset are shown in Table 4 .
Overall, the detection of normal squamous cell and dysplasia/adenocarcinoma samples was reasonably good, with a sensitivity of 79.0% and 83.3% respectively. Specificity for dysplasia/adenocarcinoma was low at 62.7%, and detection of Barrett's esophagus was poor, with only 31.3% of samples classified correctly. 3% ). This was based on the application of a training model with the ability to classify individual spectra from the training dataset with sensitivity (after cross validation) of 83.6% for normal squamous cells, 62.8% for Barrett's esophagus, and 69.5% for dysplasia/ adenocarcinoma. Certain key differences were seen between the mean spectra from the different pathology groups, which were consistent with possible biochemical differences between the cells. These included a higher glycogen content in normal squamous cells, altered mucin content in Barrett's esophagus cells, and higher DNA content in both Barrett's esophagus cells and dysplastic/adenocarcinoma cells compared with normal squamous cells.
Nonetheless there are several reasons why the results for the Barrett's esophagus cells may have been poor. The major limiting factor in this study was the small number of cells in the Barrett's esophagus training dataset. Small numbers of cells were seen on the Barrett's esophagus cell slides selected for cytopathology analysis: this was likely due to suboptimal cell preparation for the relatively smaller Barrett's esophagus cells (smaller than squamous or dysplastic cells, which tended to clump together on our cell preparation)-a difficulty of optimizing cell preparation A B C Fig. 3 Steps involved in assigning pathology labels to every cell: a unstained slide; b binary mask identifies cell regions; c training model applied to cells to assign a pathology label. BE Barrett's esophagus, DYS/AC dysplasia/adenocarcinoma, NSQ normal squamous cells Italics denote concordance between predicted pathological state and true pathological state A voting threshold was used for classification of each individual cell on a slide (30% threshold) and for classification of the sample overall (30% threshold). The sensitivity and specificity are given at the top, and the confusion matrix is given at the bottom, showing the prediction for every sample BE Barrett's esophagus, DYS/AC dysplasia/adenocarcinoma, NSQ normal squamous cells and centrifugation for different cell types. Additionally, the small Barrett's esophagus cells were likelier to be missed by our cell detection algorithm (the binary mask). This left a low number of cells that were identified by the binary mask, and also identified by both reporting cytopathologists as unequivocally representing Barrett's esophagus cells. Not only did the Barrett's esophagus group have the smallest number of cells, but these tended to be small, isolated cells (rather than a cluster of cells of the same type), and thus contained very few total spectra (76 in this group, versus 678 in the dysplasia group, and 726 in the normal squamous cell group). The training model is therefore skewed away from classifying spectra into the Barrett's esophagus group, and the Barrett's esophagus group can also more readily be affected by a small number of outlying spectra. This makes the Barrett's esophagus dataset prone to strong influence from differences due to individual samples or patients rather than true biochemical differences due to the pathological state.
High numbers of squamous cells were noted on many samples taken only from glandular regions of the esophagus. It is possible that this resulted from sampling of only the most superficial cells, which may include squamous cells that originated more proximally in the esophagus that had sloughed off and had been deposited more distally over a glandular region.
Given the presence of squamous cells seen on many slides, the relative homogeneity of the results is perhaps surprising. Although it is possible that artifact in the form of ''between-patient'' differences (as opposed to true pathological differences) contributes to this, the small number of patients in the training model relative to the test dataset makes this explanation insufficient. A further possibility is that biochemical changes precede a morphological change in cell appearance. If a region of dysplasia or adenocarcinoma underwent a field change (probably reflecting a genetic change) that preceded a phenotypic change in the cells, there may be a detectable biochemical difference in cells that appear squamous. Thus spectroscopy may be able to provide insights into biochemical changes not detectable with conventional microscopy.
A similar finding was reported in the largest study to date of infrared spectroscopy for cell classification in cervical samples: Gajjar et al. [20] found that their results correlated poorly with conventional cytology results, but showed better correlation with contemporaneous histological findings from the same region. That article cites poor cytology sensitivity and specificity as the reason for this, but an analogous explanation of field change that has not occurred in every cell (and again, particularly in the superficial cells) is another possibility. This finding is corroborated by the only previous study of FTIR spectroscopy using esophageal cells [15] , in which cells that appeared squamous were classified according to the underlying tissue histological features. This consistent finding therefore supports the theory that genetic and biochemical changes may precede morphological changes in some cells.
In that small study of ten samples, Townsend et al. [15] reported very high accuracy for classification of Barrett's esophagus and dysplasia. They reported a sensitivity to detect Barrett's esophagus versus normal squamous cells of 95.5%, normal squamous cells versus dysplasia of 93.4%, and Barrett's esophagus versus dysplasia of 88.7%. However, spectra from the same patients were included in both the test dataset and the training dataset, and since these results are drawn from a very small number of patients, it is possible that between-patient differences (as opposed to ''between pathology state'' differences) contributed to this result.
The discriminatory spectral features seen in the work of Townsend et al. are similar to the findings seen in the inverse second derivative spectra in our study and also correlate with the findings from our tissue mapping study [19] and previous FTIR work in the esophagus [12] [13] [14] . For example, the amide I peak at around 1650 cm -1 is strongest in the normal squamous cell group, the DNA peak at 1235 cm -1 is strongest in the dysplastic cell group, and the glycogen peak at 1020 cm -1 is strongest in the normal squamous cell group and almost absent in the dysplasia group. This strengthens the findings in their study, and lends further weight to an argument for an underlying biochemical difference between the pathology groups, as seen in our analysis of the inverse second derivative spectra.
There have been a small number of other studies using FTIR spectroscopy to classify cell pathology state with a similar method. These have shown the ability to classify squamous cell samples from the cervix, urinary tract, and head and neck [16, 17, 20, 21] , although this work focused on proof of concept and spectral differences, and did not provide equivalent figures for sensitivity and specificity.
The first trial data (BEST2 study) from use of the Cytosponge revealed overall sensitivity for detection of Barrett's esophagus of 79.9%, with this figure increasing to 87.2% in those with 3 cm or more of circumferential Barrett's esophagus, and a specificity of 92.4% [9] . This sensitivity is comparable to the sensitivity seen in our study for normal squamous cells (79.0%) or dysplasia/adenocarcinoma (83.3%). The BEST2 study did not attempt to discriminate dysplasia, but there are plans for work to incorporate risk stratification using DNA analysis for TP53 mutations.
Identification of Barrett's esophagus and dysplasia in combination is sufficient if it is used solely as a screening tool to identify those who require endoscopy. However, reliable detection of dysplasia could potentially replace endoscopic surveillance. The results of our study suggest that this may be achievable with FTIR spectral analysis of cells. However, this is a multistep technique that requires further optimization and validation in combination with a nonendoscopic collection device such as the Cytosponge.
The major source of variability in this study was the widely varying cell density in slide samples. Further optimization of techniques for brushing, fixation, and centrifugation may reduce this [22] .
There is much potential to refine the binary mask with a combination of further spectral information and size criteria to give a highly accurate cell identification tool. One approach could use a spectral marker of DNA (e.g., the 1234-cm -1 peak) to identify cell nuclei, in combination with associated cell cytoplasm (represented by the 1650-cm -1 peak). This could be used in combination with size criteria to quantify the amount of nuclear material present.
A two-stage analysis may be developed whereby cells are initially separated into squamous cells or columnar cells by a predictive model, and then a further analysis used to separate dysplastic and nondysplastic cells. A two-stage model was attempted with the current dataset, giving very similar results to the three-group model presented here (two-stage results not shown).
Although this study used samples collected during endoscopy to allow histological and endoscopic validation, there may be further challenges with the use of a nonendoscopic cell collection device that collects cells from the stomach and entire esophagus. The issue of differentiating pathological glandular cells from stomach cells was not examined in the present study.
Another obstacle to clinical implementation is the time needed for sample measurement. If a faster automated cell detection process could be used before infrared measurement, this would avoid measurement of large regions that do not contain cells, and would focus solely on collecting useful spectra.
Cytopathology review is a further potential source of error. In this study it was performed by two cytopathologists together, not independently. Additionally, cytopathologists are not used to reviewing single cells in isolation, but more usually look at a whole sample for assessment. Presentation of cells in isolation could mean the decision is affected by variable staining between slides, which might be accounted for if the slide is taken as a whole.
One of the major obstacles to future work in this area is obtaining a reliable gold standard against which the training model can be tested. The poor sensitivity and specificity in comparable fields (e.g., cervical cytology) suggests that this may limit the usefulness of cytology as a gold standard. Comparison with histological findings (as in the whole sample test dataset) may be more accurate.
Although the relatively poor sensitivity and specificity of cytology causes problems for testing, this supports an argument for the development of spectral cytopathology since this an area in which diagnostic performance could readily be improved. This technology could potentially be applied in a range of different diseases and organ systems.
Conclusions
FTIR spectroscopy offers a potential automated method of identifying Barrett's neoplasia in esophageal cell samples. Accurate identification of neoplasia could augment or replace current models of endoscopic surveillance. High sensitivity for neoplasia would be a key feature if used in clinical practice, but further work is needed to optimize the current technique and increase specificity before clinical translation. The low sensitivity for nondysplastic Barrett's esophagus of the present technique is not suitable for screening purposes.
